Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial

Imagem de Miniatura
Arquivos
art_FURTADO_Dapagliflozin_and_Cardiovascular_Outcomes_in_Patients_With_Type_2019.PDF (711.1 KB)
Citações na Scopus
239
Tipo de produção
article
Data de publicação
2019
Editora
LIPPINCOTT WILLIAMS & WILKINS
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
BONACA, Marc P.
RAZ, Itamar
ZELNIKER, Thomas A.
MOSENZON, Ofri
CAHN, Avivit
KUDER, Julia
MURPHY, Sabina A.
BHATT, Deepak L.
LEITER, Lawrence A.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CIRCULATION, v.139, n.22, p.2516-2527, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Sodium glucose transporter-2 inhibitors reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus and a history of atherosclerotic cardiovascular disease. Because of their baseline risk, patients with previous myocardial infarction (MI) may derive even greater benefit from sodium glucose transporter-2 inhibitor therapy. Methods: DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58) randomized 17 160 patients with type 2 diabetes mellitus and either established atherosclerotic cardiovascular disease (n=6974) or multiple risk factors (n=10 186) to dapagliflozin versus placebo. The 2 primary end points were composite of MACE (cardiovascular death, MI, or ischemic stroke) and the composite of cardiovascular death or hospitalization for heart failure. Those with previous MI (n=3584) made up a prespecified subgroup of interest. Results: In patients with previous MI (n=3584), dapagliflozin reduced the relative risk of MACE by 16% and the absolute risk by 2.6% (15.2% versus 17.8%; hazard ratio [HR], 0.84; 95% CI, 0.72-0.99; P=0.039), whereas there was no effect in patients without previous MI (7.1% versus 7.1%; HR, 1.00; 95% CI, 0.88-1.13; P=0.97; P for interaction for relative difference=0.11; P for interaction for absolute risk difference=0.048), including in patients with established atherosclerotic cardiovascular disease but no history of MI (12.6% versus 12.8%; HR, 0.98; 95% CI, 0.81-1.19). There seemed to be a greater benefit for MACE within 2 years after the last acute event (P for interaction trend=0.007). The relative risk reductions in cardiovascular death/hospitalization for heart failure were more similar, but the absolute risk reductions tended to be greater: 1.9% (8.6% versus 10.5%; HR, 0.81; 95% CI, 0.65-1.00; P=0.046) and 0.6% (3.9% versus 4.5%; HR, 0.85; 95% CI, 0.72-1.00; P=0.055) in patients with and without previous MI, respectively (P interaction for relative difference=0.69; P interaction for absolute risk difference=0.010). Conclusions: Patients with type 2 diabetes mellitus and previous MI are at high risk of MACE and cardiovascular death/hospitalization for heart failure. Dapagliflozin appears to robustly reduce the risk of both composite outcomes in these patients. Future studies should aim to confirm the large clinical benefits with sodium glucose transporter-2 inhibitors we observed in patients with previous MI.
Palavras-chave
myocardial infarction, sodium-glucose transporter 2 inhibitors, type 2 diabetes mellitus
URI
https://observatorio.fm.usp.br/handle/OPI/33443
Referências
  1. Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5
  2. Bhatt DL, 2016, J AM COLL CARDIOL, V67, P2732, DOI 10.1016/j.jacc.2016.03.529
  3. Bhatt DL, 2010, JAMA-J AM MED ASSOC, V304, P1350, DOI 10.1001/jama.2010.1322
  4. Bonaca MP, 2018, CIRCULATION, V137, P338, DOI 10.1161/CIRCULATIONAHA.117.032235
  5. Bonaca MP, 2015, NEW ENGL J MED, V372, P1791, DOI 10.1056/NEJMoa1500857
  6. Cavender MA, 2015, CIRCULATION, V132, P923, DOI 10.1161/CIRCULATIONAHA.114.014796
  7. Cefalu WT, 2019, DIABETES CARE, V42, pS90, DOI 10.2337/dc19-S009
  8. Das SR, 2018, J AM COLL CARDIOL, V72, P3200, DOI 10.1016/j.jacc.2018.09.020
  9. Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI 10.2337/dci18-0033
  10. Fitchett D, 2019, CIRCULATION, V139, P1384, DOI 10.1161/CIRCULATIONAHA.118.037778
  11. GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862
  12. Heerspink HJL, 2013, DIABETES OBES METAB, V15, P853, DOI 10.1111/dom.12127
  13. Heerspink HJL, 2016, CIRCULATION, V134, P752, DOI 10.1161/CIRCULATIONAHA.116.021887
  14. Inzucchi SE, 2018, DIABETES CARE, V41, pE4, DOI 10.2337/dc17-1551
  15. Januzzi JL, 2017, J AM COLL CARDIOL, V70, P704, DOI 10.1016/j.jacc.2017.06.016
  16. Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
  17. Lin B, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/s12933-014-0148-1
  18. Morrow DA, 2009, CIRCULATION, V119, P2758, DOI 10.1161/CIRCULATIONAHA.108.833665
  19. Neal B, 2017, NEW ENGL J MED, V377, P644, DOI 10.1056/NEJMoa1611925
  20. Packer M, 2017, JAMA CARDIOL, V2, P1025, DOI 10.1001/jamacardio.2017.2275
  21. Rawshani A, 2017, NEW ENGL J MED, V376, P1407, DOI 10.1056/NEJMoa1608664
  22. Raz I, 2018, DIABETES OBES METAB, V20, P1102, DOI 10.1111/dom.13217
  23. Sabatine MS, 2018, CIRCULATION, V138, P756, DOI 10.1161/CIRCULATIONAHA.118.034309
  24. Sabatine MS, 2017, LANCET DIABETES ENDO, V5, P941, DOI 10.1016/S2213-8587(17)30313-3
  25. Sandoval Y, 2014, J AM COLL CARDIOL, V63, P2079, DOI 10.1016/j.jacc.2014.02.541
  26. Sarwar N, 2010, LANCET, V375, P2215, DOI 10.1016/S0140-6736(10)60484-9
  27. Thygesen K, 2012, CIRCULATION, V126, P2020, DOI 10.1161/CIR.0b013e31826e1058
  28. Torabi A, 2008, EUR HEART J, V29, P859, DOI 10.1093/eurheartj/ehn096
  29. Unnikrishnan R, 2017, DIABETES, V66, P1432, DOI 10.2337/db16-0766
  30. Verma S, 2018, CIRCULATION, V138, P2884, DOI 10.1161/CIRCULATIONAHA.118.034516
  31. Verma Subodh, 2018, JACC Basic Transl Sci, V3, P575, DOI 10.1016/j.jacbts.2018.07.006
  32. Verma S, 2018, DIABETOLOGIA, V61, P2108, DOI 10.1007/s00125-018-4670-7
  33. Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI 10.1056/NEJMoa1812389
  34. Wiviott SD, 2018, AM HEART J, V200, P83, DOI 10.1016/j.ahj.2018.01.012
  35. Zelniker TA, 2019, LANCET, V393, P31, DOI 10.1016/S0140-6736(18)32590-X
  36. Zelniker TA, 2018, J AM COLL CARDIOL, V72, P1845, DOI 10.1016/j.jacc.2018.06.040
  37. Zinman B, 2015, NEW ENGL J MED, V373, P2117, DOI 10.1056/NEJMoa1504720

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - ODS/03